Multiple Myeloma: Big Survival Gains From Novel Agents In The Real World
Evangelos Terpos, University of Athens
/
RSS Feed
Evangelos Terpos, University of Athens
Big improvements in survival among patients with multiple myeloma were reported at the European Hematology Association annual congress in Barcelona by Greek researchers looking at the past decade of therapy with the novel agents: thalidomide, lenalidomide and bortezomib in the “real world” setting. Professor Evangelos Terpos from the University of Athens discusses his groups findings on bone metabolism under novel agent therapy and assesses the impact of these drugs on survival among patients in Greece.
LISTEN
[audio:https://www.audiomedica.com/podcasting/oncology/100628EvangelosTerposPODCAST.mp3]
You may also like...
Audio Journal of Oncology in Advance – March 1st, 2007 2 Mar, 2007 
Low risk localized prostate cancer: no harm from waiting! 16 Mar, 2013 
Gene expression and molecular pathways guide head and neck cancer therapies 24 Apr, 2013 - BRCA1/2 Ovarian Cancer—Three Years Disease Free with First-Line Olaparib 1 Nov, 2018
